Skip to search formSkip to main contentSkip to account menu

LY 2140023

Known as: LY-2140023, LY2140023 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Amino Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
In Vitro Characterization of the Bioconversion of Pomaglumetad Methionil, a Novel Metabotropic Glutamate 2/3 Receptor Agonist Peptide Prodrug
To characterize the hydrolysis of the peptide prodrug pomaglumetad methionil (LY2140023; (1R,4S,5S,6S)-4-(L-methionylamino)-2… 
2014
2014
A Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of a Metabotropic Glutamate 2/3 Receptor Agonist Using an Electronic Patient-Reported Outcome Device in Patients With…
Abstract This 6-week, multicenter, randomized withdrawal, placebo-controlled trial sought to determine whether symptoms of… 
2013
2013
Clinical development of pomaglumetad methionil: A non-dopaminergic treatment for schizophrenia
2012
2012
Adverse Events in Healthy Subjects Exposed to Single and Multiple Doses of LY2140023 Monohydrate: Pooled Results From 10 Phase 1 Studies
Abstract Ten phase 1 studies of LY2140023 monohydrate (LY2140023), an mGlu2/3 receptor agonist, in healthy male and female… 
Review
2012
Review
2012
Antipsychotic dosing: extended, and transient.
New Ways of Antipsychotic Dosing Considering the few new medications being developed for schizophrenia, it is recognized that… 
Review
2011
Review
2011
Progress in the developement of positive allosteric modulators of the metabotropic glutamate receptor 2.
The metabotropic glutamate type 2 (mGlu2) receptor is a G-protein coupled receptor (GPCR) expressed on presynaptic nerve… 
2011
2011
mGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial
Anomalies in glutamatergic neurotransmission are currently believed to be one of the pathogenetic factors in schizophrenia and… 
2010
2010
[The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial].
Glutamate neurotransmission has been considered as one of pathogenetic factors of schizophrenia though all antipsychotics widely… 
Review
2010
Review
2010
[Targeting metabotropic glutamate receptors to develop novel antipsychotics].
Based on the glutamate hypothesis of schizophrenia, extensive studies to develop drugs acting on glutamate receptors have been… 
2009
2009
Neue Erkenntnisse zur Genetik der Schizophrenie
ZusammenfassungDie Aufklärung der Pathogenese der Schizophrenie kommt derzeit gut voran. Die Bedeutung des Glutamatsystems und… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)